HanchorBio Announces Approval for Multi-Regional Clinical Trial of HCB101

HanchorBio has received approval from the Taiwan Food and Drug Administration (TFDA) for its investigational new drug (IND) application, enabling them to proceed with a multi-regional clinical trial of their novel drug candidate, HCB101. This drug is being developed to treat patients with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma.

HCB101 is created using structure-guided protein design and engineering, along with relevant screening technologies. It consists of an engineered extracellular domain of SIRPα fused to the Fc region of IgG4.

This innovative drug works by triggering the phagocytic activity of macrophages, blocking the "do not eat" signal between macrophages and tumour cells. The extensive in-vitro and in-vivo preclinical data suggest that HCB101 could be a safer and more potent biologic compared to the anti-CD47 monoclonal antibodies and SIRPa fusion proteins currently under investigation in clinical trials.

The clinical trial, known as HCB101-101, will be a multi-regional, multi-centre, open-label, dose-finding, first-in-human (FIH) study involving adults with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma in both the United States and Taiwan. The primary objectives of this study are to assess the safety, tolerability, pharmacokinetics, and clinical anti-tumour activity of weekly HCB101 intravenous injections.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!